U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07080346) titled 'Upadacitinib for Refractory Behcet's Syndrome' on July 15.
Brief Summary: Behcet's syndrome (BS) is a systemic autoimmune vasculitis that can affect multiple organs, including the skin, eyes, and vascular system. Refractory BS poses significant treatment challenges, necessitating novel therapeutic approaches. Upadacitinib, a selective JAK1 inhibitor within the JAK-STAT pathway, has shown promise in modulating immune responses. This study aims to evaluate the efficacy and safety of upadacitinib in patients with refractory BS.
Study Start Date: Jan. 25, 2024
Study Type: INTERVENTIONAL
Condition:
Behcet Syndrome
Intervention:
DRU...